Comparison of Double-tract and Tubular Gastric Anastomosis in Proximal Gastric Cancer
NCT07635836
Summary
This study includes patients diagnosed with proximal gastric cancer (Siewert type II/III, cT1-3N0-1M0) across six tertiary hospitals, who underwent either double-tract reconstruction (DTR) or tubular gastric anastomosis (TGA). Participants were divided into two groups based on the surgical procedure. We conducted a comparative analysis of postoperative outcomes by evaluating electronic medical records, postoperative gastroscopy, 24-hour esophageal pH monitoring, and relevant rating scales.
Eligibility
Inclusion Criteria: * Pathologically confirmed gastric adenocarcinoma by biopsy * Carcinoma of the upper gastric body or Siewert type II/III adenocarcinoma of the esophagogastric junction (AEG), with a clinical stage of cT1-3N0-1M0 * Age 18-75 years, with a performance status (PS) score of 0-2 * Candidates for planned surgical resection, eligible for either double-tract reconstruction or tubular gastric anastomosis based on preoperative assessment * No severe dysfunction of vital organs (liver, kidney, heart, lung, or brain), and no severe infection or uncontrolled chronic diseases Exclusion Criteria: * Presence of other malignant tumors or severe chronic diseases (e.g., severe diabetes mellitus, chronic kidney disease, decompensated cirrhosis, etc.) * Preoperative endoscopic diagnosis of Barrett's esophagus * Severe preoperative malnutrition (albumin \<30 g/L, prealbumin \<150 mg/L) * History of prior upper abdominal surgery, gastrointestinal malformation, or psychiatric disorders * Preoperative diagnosis of obstructive motor disorders of the cardia (including achalasia spectrum disorders) * Inability to cooperate with or complete the required postoperative examinations
Conditions4
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07635836